Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases

Nanoparticles (NPs) are differing in particle size, charge, shape, and compatibility of targeting ligands, which are linked to improved pharmacologic characteristics, targetability, and bioavailability. Researchers are now tasked with developing a solution for enhanced renal treatment that is free of side effects and delivers the medicine to the active spot. A growing number of nano-based medication delivery devices are being used to treat renal disorders. Kidney disease management and treatment are currently causing a substantial global burden. Renal problems are multistep processes involving the accumulation of a wide range of molecular and genetic alterations that have been related to a variety of kidney diseases. Renal filtration is a key channel for drug elimination in the kidney, as well as a burgeoning topic of nanomedicine. Although the use of nanotechnology in the treatment of renal illnesses is still in its early phases, it offers a lot of potentials. In this review, we summarized the properties of the kidney and characteristics of drug delivery systems, which affect a drug’s ability should focus on the kidney and highlight the possibilities, problems, and opportunities.

Study on covert administration of medications practices among persons with severe mental illness: A cross-sectional study

Background: Covert administration of medication (CoAdM) by caregivers to persons with severe mental illness (SMI) is a commonly observed medication delivery practice in India. Aims: This study aims to examine different medication delivery practices adopted by caregivers to provide care to SMI at times of medication refusal. Method: This study was conducted at the outpatient department between April 2019 and November 2019. A semi-structured questionnaire was used to interview the caregivers of persons with SMI to assess medication delivery practices. Results: A total of 300 caregivers were interviewed. CoAdM was practiced in 96 (32.0%) persons with SMI at least once during their lifetime, and other strategies used were pleading ( n = 105, 35.0%), lying ( n = 10, 3.3%), and threatening ( n = 154, 51.4%). Logistic regression showed that male gender (OR 4.75; CI 1.37–16.46), absent insight (OR 10.0; CI 2.01–47.56), and poor adherence to medication (OR 4.75; CI 1.31–16.92) were significantly associated with CoAdM in the last 1 year. Caregivers perceived significant improvement in self-care ( Z = −4.37, p < .01), interpersonal ( Z = −7.61, p < .01), work ( Z = −5.9, p < .01), family functioning ( Z = −7.82, p < .01) difficult behavior ( Z = −8.27, p < .01), and dependency ( Z = −6.34, p < .01) in persons with SMI with use of CoAdM. Conclusions: CoAdM was given to one in three persons with SMI at some point in their lives. Male gender, absent insight and poor adherence were predictive of CoAdM in the last 1 year. Caregiver perceived improvements in self-care, work, interpersonal, family functioning, problem behaviors, and dependency after CoAdM. Policies need to be evolved to serve all stakeholders while keeping these practices in mind.

The Impact of Delayed Symptomatic Treatment Implementation in the Intensive Care Unit

We estimated the harm related to medication delivery delays across 12,474 medication administration instances in an intensive care unit using retrospective data in a large urban academic medical center between 2012 and 2015. We leveraged an instrumental variables (IV) approach that addresses unobserved confounds in this setting. We focused on nurse shift changes as disruptors of timely medication (vasodilators, antipyretics, and bronchodilators) delivery to estimate the impact of delay. The average delay around a nurse shift change was 60.8 min (p < 0.001) for antipyretics, 39.5 min (p < 0.001) for bronchodilators, and 57.1 min (p < 0.001) for vasodilators. This delay can increase the odds of developing a fever by 32.94%, tachypnea by 79.5%, and hypertension by 134%, respectively. Compared to estimates generated by a naïve regression approach, our IV estimates tend to be higher, suggesting the existence of a bias from providers prioritizing more critical patients.

A Novel Drug Delivery System: Floating Microspheres in the Development of Gastroretentive Drug Delivery System

Gastric emptying is a complicated process in the human body because it is very inconstant, resulting in ambiguous in vivo drug delivery system efficacy. To combat this variability, scientists have been working on developing a regulated medication delivery system with a long gastric residence period. This review article on gastroretentive drug delivery systems (GRDDS) focuses on numerous gastroretentive approaches that have recently emerged as a leading methodology in the field of site-specific orally administered controlled release drug administration. Gastroretentive medicines come in a variety of forms on the market, including tablets, granules, capsules, floating microspheres, laminated films, and powders. Floating microspheres are currently garnering more attention than previous techniques because of their benefits, which include more consistent drug absorption and a lower risk of local discomfort. The primary goal of this method is to increase gastric retention time in the GIT, which is defined as more than 12 hours in the stomach with an absorption window in the upper small intestine. Longer stomach retention improves bioavailability, reduces drug waste, and boosts solubility for medications that are less soluble in a high pH environment. The medicines are released into the stomach for a long time and consistently thanks to the floating microsphere systems. The current study compiles the most recent research on the techniques of production, characterization, and numerous aspects that impact the performance of floating microspheres for oral administration.

A Review on Nanoparticles: Preparation and Characterization of Nanoparticles

The development of innovative medication delivery systems has increased at an exponential rate in the last few years. Nanoparticles are particles with a size of between one and one hundred nanometers. Nanoparticles provide substantial benefits over conventional drug administration in terms of high bioavailability, high stability, high drug-carrying capacity, and other characteristics. This review concentrated mostly on the classification of nanoparticles, the technique of synthesis, the evaluation of nanoparticles, and the list of FDA-approved nanomedicines now available on the market.

Microencapsulation Technology a Holistic Approach in the Field of Pharmaceutical Sciences a Review

Microencapsulation is a technique that uses a coating to encapsulate microscopic particles or droplets in order to generate miniature capsules with therapeutic properties. The substance contained within the microcapsule is referred to as the core, internal phase, or fill, whereas the wall is referred to as a shell, coating, or membrane. A microcapsule is a small object that contains essential items, internal components, or fillers and is encased by a shell, cover, or membrane. Microcapsules range in size from 1 to 1000 micrometres. This approach is frequently used for medication administration, molecular protection, and robustness. The microencapsulation programme has been established as a different delivery mechanism for multiple treatment regimens and offers potential benefits beyond those of normal medication delivery systems. Microencapsulation is a well-established review dedicated to the preparation, properties, and applications of individually encapsulated novel small particles, as well as significant improvements to tried-and-tested techniques relevant to micro and nano particles and their use in a wide range of industrial, engineering, pharmaceutical, biotechnology, and research applications. Its scope extends beyond conventional microcapsules to all other small particulate systems, such as self-assembling structures that involve preparative manipulation.

Nanobot: Artificial Intelligence, Drug Delivery and Diagnostic Approach

The design, construction, and programming of robots with overall dimensions of less than a few micrometres, as well as the programmable assembly of nanoscale items, are all part of nanorobotics. Nanobots are the next generation of medication delivery systems, as well as the ultimate nanoelectromechanical systems. Nano bioelectronics are used as the foundation for manufacturing integrated system devices with embedded nano biosensors and actuators in the nanorobot architectural paradigm, which aids in medical target identification and drug delivery. Nanotechnology advances have made it possible to create nanosensors and actuators using nano bioelectronics and biologically inspired devices. The creation of nanobots is fascinated by both top-down and bottom-up approaches. The qualities, method of synthesis, mechanism of action, element, and application of nanobots for the treatment of nervine disorders, wound healing, cancer diagnosis study, and congenital disease were highlighted in this review. This method gives you a lot of control over the situation and helps with sickness diagnosis.

Review on Nanotechnology and its utilization in Pharmaceuticals

Nanotechnology is the study of tiny structures ranging in size from 0.1 to 100 nanometers. It includes biophysics, molecular biology, and bioengineering, as well as medical subspecialties such as cardiology, ophthalmology, endocrinology, oncology, and immunology. Pharmaceutical Nanotechnology combines the methods and ideas of nanoscience and nanomedicine with pharmacy to create novel medication delivery systems that transcend the limitations of traditional drug delivery systems. The purpose of this article is to provide an overview of nanotechnology and its uses in the pharmaceutical industry.